PGmax™ - Comprehensive Ocular Disorders Panel
Use
The PGmax™ - Comprehensive Ocular Disorders Panel is designed for individuals who have a clinical or suspected diagnosis of an inherited ocular disorder. It is also suitable for individuals experiencing overlapping symptoms from multiple eye disorders that require broad genetic analysis, as well as for those with eye disorders that are part of multi-systemic conditions. The test analyzes 644 genes associated with ocular disorders.
Special Instructions
This test uses NGS with CNV on either the Exome or Genome platform. Exome platform includes blood, DNA, buccal, saliva, or tissue specimens, while genome platform includes blood and DNA. STAT testing is available with a 25% surcharge.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration. Due to the nature of NGS, there might be regions of the genome that are not adequately covered by sequencing, leading to undetected variants.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
7-16 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided